BASED MEDIMMUNE, WHICH MAKES A NEEDLE-FREE, NASAL-SPRAY VACCINE, SAID IT WOULD EXPAND ITS FACILITIES.
"WE PLAN TO EXPAND OUR DOMESTIC MANUFACTURING CAPACITY BY ESTABLISHING A CELL-BASED FACILITY IN THE UNITED STATES THAT CAN PRODUCE AT LEAST 150 (...)
